• Search Funds
  • Model Portfolios
  • Provider
  • Sector
  • Manager

Search by provider name

Search by sector name

Search by manager name

Search by Risk Level

AXA Framlington Biotech Fund Z Acc

  • Fund Info & charges
  • Performance
  • Fund breakdown
  • Dividend History
Fund Provider AXA Investment Managers UK Limited
Fund Summary The aim of this Fund is to provide long-term capital growth.
SEDOL code B784NS1
ISIN GB00B784NS11
Fund code FMBTA
Managers Linden Thomson, Dani Saurymper
Manager Tenure 7 years
Morningstar Category Sector Equity Biotechnology
IMA Sector Specialist
Fund Size £422 million
Fund Type OEIC
Management Style Active
Total Expense Ratio (TER) 0.82%
Cavendish ongoing charge 0.05%
FundsNetwork Service Fee 0.20%
Minimum Initial Investment £25
Minimum Top Up £25
Minimum Monthly Investment £25
Sell Price £3.502
Buy Price £3.502
Price Change +1.8023%
Price Date 16th July 2019
Yield Currently unavailable
Dividend Frequency Semi-Annually
ISA Eligible Yes
SIPP Eligible Yes
Inception Date 27th November 2001
Fund Status OPEN

3-year Mean Monthly Return: 1.075%

Annual Returns 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009
Fund Performance +1.05% +7.85% +27.17% -21.98% +56.18% +33.86% +40.87% +22.02% +23.29% +0.92%
Benchmark Performance
(Sector Equity Biotechnology)
-0.50% +8.48% +28.16% -20.86% +48.04%
Time Period Cumulative Benchmark Performance
(Sector Equity Biotechnology)
Fund Compared to Benchmark
1 day 1.80% -0.48% +2.28%
1 week 0.11% -0.45% +0.56%
1 month 3.43% +0.44% +2.98%
3 months -0.03% -5.05% +5.02%
6 months 2.07% +0.12% +1.95%
1 year -5.61% -2.15% -3.45%
3 years 32.40% +31.77% +0.63%
5 years 76.82% +65.47% +11.36%
10 years 402.07% +372.96% +29.11%
YTD 17.67% +10.66% +7.01%
Since inception 312.39% Currently unavailable Currently unavailable

Top 10 shares for this fund

Share Name Country Value
Gilead Sciences Inc USA 7.33%
Celgene Corp USA 6.90%
Alexion Pharmaceuticals Inc USA 6.80%
Biogen Inc USA 6.21%
Amgen Inc USA 4.65%
Biomarin Pharmaceutical Inc USA 3.41%
Vertex Pharmaceuticals Inc USA 3.15%
Illumina Inc USA 3.06%
Takeda Pharmaceutical Co Ltd JPN 2.88%
Regeneron Pharmaceuticals Inc USA 2.64%

Currently unavailable